Express | Research Articles on COVID-19 Published by WIV Scientists

Date:19-04-2020   |   【Print】 【close

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2

Jiang RD, Liu MQ, Chen Y, et al.


Published: 9 July 2020;182(1):50-58.e8.



Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques

Shan C, Yao YF, Yang XL, et al.

Cell Res.

Published: 7 July 2020; 1-8.



Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients

Wang C, Xie J, Zhao L, et al.


Published: 20 June 2020; 57:102833.



Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients

Xu ZS, Shu T, Kang L, et al. 

Signal Transduct Target Ther.

Published: 19 June 2020; 5(1):100.



Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Yi C, Sun X, Ye J, et al.

Cell Mol Immunol.

Published: 16 June 2020;17(6):621-630.



Co-infection of SARS-CoV-2 and Influenza virus in Early Stage of the COVID-19 Epidemic in Wuhan, China

Zheng X, Wang H, Su Z, et al.

J Infect.

Published: 28 May 2020; S0163-4453(20)30319-4



A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

Shi, R., Shan, C., Duan, X. et al.


Published: 26 May 2020



Structural basis for RNA replication by the SARS-CoV-2 polymerase

Wang Q, Wu J, Wang H, et al.


Published: 22 May 2020



Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2

Jiang R, Liu M, Chen Y, et al.


Published: 21 May 2020



Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture

Zhang Y, Zhang Q, Li X, et al.

Emerging Microbes & Infections

Published: 20 May 2020



Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Yi C, Sun X, Ye J, et al.

Cell Mol Immunol.

Published: 15 May 2020



Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur

Jin Z, Zhao Y, Sun Y, et al.

Nat Struct Mol Biol.

Published: 07 May 2020



The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro

Wang, X., Cao, R., Zhang, H. et al.

Cell Discov 6, 28 (2020)

Published: 02 May 2020



The Importance Of Naturally Attenuated Sars-Cov-2 In The Fight Against Covid-19

Armengaud J, Delaunay-Moisan A, Thuret JY, et al.

Environ Microbiol.

Published: 28 April 2020



Plasma Metabolomic and Lipidomic Alterations Associated with COVID-19

Wu D, Shu T, Yang X, et al.

National Science Review

Published: 28 April 2020



SARS-CoV-2 Infection in Children 

Lu X, Zhang L, Du H, et al.

N Engl J Med., 382(17):1663–1665

Published: 23 April 2020



Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Dai W, Zhang B, Jiang X, et al.


Published: 22 April 2020



Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Chen X, Zhao B, Qu Y, et al.

Clin Infect Dis.

Published: 17 April 2020



SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells

Mu J, Xu J, Zhang L, et al.

Sci China Life Sci.



Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors

Jin Z, Du X, Xu Y, et al.


Published: 9 April 2020



Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay

Yan C, Cui J, Huang L, et al.

Clin Microbiol Infect.

Published: 7 April 2020



Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Duan K, Liu B, Li C, et al.


Published: 6 April 2020



Inhibition of SARS-CoV-2 (Previously 2019-nCoV) Infection by a Highly Potent Pan-Coronavirus Fusion Inhibitor Targeting Its Spike Protein That Harbors a High Capacity to Mediate Membrane Fusion

Xia S, Liu M, Wang C, et al.

Cell Research, 30(4):343-355

Published: 30 March 2020



Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Liu J, Cao R, Xu M, et al. 

Cell Discovery volume 6, Article number: 16 (2020)

Published: 18 March 2020



A distinct name is needed for the new coronavirus

Jiang S, Shi Z, Shu Y, et al.

Lancet, 395(10228):949

Published: 19 Feburary 2020



Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Zhang W, Du RH, Li B, et al.

Emerg Microbes Infect., 9(1):386-389

Published: 17 Feburary 2020



Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Tian X, Li C, Huang A, et al.

Emerg Microbes Infect., 9(1):382–385

Published: 17 Feburary 2020



The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus

Jiang S, Shi ZL

Virol Sin.

Published: 14 Feburary 2020



Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

Xia S, Zhu Y, Liu M, et al.

Cell Mol Immunol.

Published: 11 Feburary 2020



Clinical Features and Treatment of 2019-nCov Pneumonia Patients in Wuhan: Report of A Couple Cases

Zhang Z, Li X, Zhang W, Shi ZL, Zheng Z, Wang T.

Virol Sin.

Published: 7 Feburary 2020



Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro 

Wang M, Cao R, Zhang L, et al.

Cell Research volume 30, pages 269–271

Published: 04 February 2020



A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou P, Yang XL, Wang XG, et al.

Nature volume 579, pages 270–273

Published: 03 February 2020



An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies

Jiang S, Du L, Shi Z.

Emerg Microbes Infect., 9(1):275-277

Published: 31 January 2020